PFIZER INC. AND SUBSIDIARY COMPANIES
RECASTED PRODUCT REVENUE TABLES
SUPPLEMENTAL INFORMATION

Pfizer is providing the attached recasted unaudited historical product revenue tables for each of the quarters and full year 2023 to conform to our new presentation, which streamlines this information to focus on the performance of key products and potential future growth drivers, as well as to reflect the below changes which were effective January 1, 2024:

- Reclassified royalty income (substantially all of which is related to Biopharma) from *Other (income)/deductions—net* to revenues and began presenting *Royalty revenues* as a separate line item within *Total revenues* in our consolidated statements of income.

- Made changes in our commercial organization to incorporate Seagen Inc. Specifically, within our Biopharma reportable segment we created the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division.

Prior-period amounts reflected in the 2023 Product Revenue Tables have been recasted to conform to the current presentation. These changes have no impact on our previously reported consolidated operating income or net income.

For additional information regarding the changes in Pfizer's commercial organizational structure, see the *Item 1. Business—Commercial Operations* section of Pfizer's 2023 Annual Report on Form 10-K (available at www.pfizer.com and www.sec.gov), Pfizer's first quarter 2024 earnings release once it is furnished on Form 8-K with the U.S. Securities and Exchange Commission (SEC), which is expected to be on or about May 1, 2024, and Pfizer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 once it is filed with the SEC, which is expected to be on or about May 8, 2024.

PFIZER INC. REVENUES
FIRST-QUARTER 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 18,486**	**$ 25,833**	**(28%)**	**(26%)**	**$ 8,711**	**$ 9,091**	**(4%)**	**$ 9,775**	**$ 16,743**	**(42%)**	**(37%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 18,173**	**$ 25,494**	**(29%)**	**(26%)**	**$ 8,598**	**$ 8,988**	**(4%)**	**$ 9,575**	**$ 16,507**	**(42%)**	**(38%)**
Primary Care	**$ 11,560**	**$ 18,899**	**(39%)**	**(36%)**	**$ 5,142**	**$ 5,742**	**(10%)**	**$ 6,418**	**$ 13,157**	**(51%)**	**(48%)**
Paxlovid	4,069	1,470	*	*	1,960	1,015	93%	2,109	455	*	*
Comirnaty[b][c]	3,064	13,228	(77%)	(75%)	329	2,315	(86%)	2,735	10,913	(75%)	(73%)
Eliquis[b]	1,874	1,793	5%	7%	1,261	1,080	17%	613	713	(14%)	(8%)
Prevnar family[d]	1,602	1,565	2%	5%	1,084	1,014	7%	518	551	(6%)	0%
Nurtec ODT/Vydura	167	1	*	*	163	—	*	4	1	*	*
Premarin family	112	102	10%	11%	104	94	11%	9	8	3%	10%
All other Primary Care	672	741	(9%)	(4%)	241	224	7%	432	517	(16%)	(9%)
Specialty Care	**$ 3,616**	**$ 3,510**	**3%**	**8%**	**$ 1,473**	**$ 1,281**	**15%**	**$ 2,143**	**$ 2,229**	**(4%)**	**4%**
Vyndaqel family[e]	686	612	12%	16%	384	265	45%	302	347	(13%)	(7%)
Sulperazon	320	210	52%	64%	—	—	—	320	210	52%	64%
Xeljanz	237	372	(36%)	(33%)	90	203	(55%)	147	169	(13%)	(6%)
Enbrel (Outside the U.S. and Canada)	199	280	(29%)	(22%)	—	—	—	199	280	(29%)	(22%)
Inflectra	178	135	32%	35%	119	79	52%	59	56	5%	11%
Zithromax	150	125	19%	30%	0	1	(39%)	149	124	20%	30%
Genotropin	147	80	85%	96%	67	7	*	80	72	10%	22%
Zavicefta	116	104	12%	22%	—	—	—	116	104	12%	22%
BeneFIX	109	112	(2%)	3%	59	61	(4%)	50	50	—	11%
Oxbryta	71	—	*	—	71	—	*	0	—	*	—
Cibinqo	16	5	*	*	8	3	*	8	2	*	*
All other Hospital[f]	1,197	1,283	(7%)	(3%)	603	589	2%	593	694	(14%)	(8%)
All other Specialty Care	188	194	(3%)	3%	70	74	(5%)	118	120	(1%)	8%
Oncology	**$ 2,997**	**$ 3,085**	**(3%)**	**(0%)**	**$ 1,983**	**$ 1,965**	**1%**	**$ 1,014**	**$ 1,120**	**(10%)**	**(2%)**
Ibrance	1,144	1,237	(8%)	(5%)	750	753	—	394	484	(19%)	(12%)
Oncology biosimilars[h]	412	460	(10%)	(9%)	300	353	(15%)	112	107	5%	12%
Xtandi[g]	339	343	(1%)	(1%)	339	343	(1%)	—	—	—	—
Inlyta	259	234	11%	14%	155	140	11%	104	94	11%	18%
Bosulif	150	128	17%	21%	105	82	29%	44	46	(3%)	6%
Lorbrena	112	72	56%	63%	52	39	32%	61	33	84%	99%
Xalkori	111	127	(13%)	(8%)	27	24	13%	83	103	(19%)	(13%)
Braftovi/Mektovi	103	104	(1%)	(1%)	99	104	(4%)	3	0	*	*
Talzenna	10	11	(5%)	1%	5	6	(24%)	6	5	18%	32%
All other Oncology[i]	356	370	(4%)	1%	150	121	24%	207	249	(17%)	(10%)
BUSINESS INNOVATION	**$ 313**	**$ 339**	**(8%)**	**(5%)**	**$ 113**	**$ 103**	**9%**	**$ 200**	**$ 236**	**(15%)**	**(11%)**
Pfizer CentreOne[j]	308	339	(9%)	(6%)	108	103	5%	200	236	(15%)	(11%)
Pfizer Ignite	4	—	*	—	4	—	*	—	—	—	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 6,615**	**$ 7,023**	**(6%)**				
Pfizer Oncology Division					**$ 1,983**	**$ 1,965**	**1%**				
Pfizer International Division								**$ 9,575**	**$ 16,507**	**(42%)**	**(38%)**

Total Alliance revenues included above	**$ 2,060**	**$ 2,314**	**(11%)**	**(9%)**	**$ 1,580**	**$ 1,387**	**14%**	**$ 480**	**$ 927**	**(48%)**	**(44%)**
Total Royalty revenues included above	**$ 204**	**$ 173**	**18%**	*****	**$ 204**	**$ 173**	**18%**				

PFIZER INC. REVENUES
SECOND-QUARTER 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 13,007**	**$ 27,958**	**(53%)**	**(52%)**	**$ 6,458**	**$ 11,439**	**(44%)**	**$ 6,548**	**$ 16,519**	**(60%)**	**(59%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 12,690**	**$ 27,639**	**(54%)**	**(53%)**	**$ 6,367**	**$ 11,350**	**(44%)**	**$ 6,323**	**$ 16,289**	**(61%)**	**(59%)**
Primary Care	**$ 5,884**	**$ 21,013**	**(72%)**	**(71%)**	**$ 2,582**	**$ 7,824**	**(67%)**	**$ 3,303**	**$ 13,190**	**(75%)**	**(74%)**
Comirnaty[b][c]	1,488	8,849	(83%)	(82%)	16	1,081	(98%)	1,471	7,768	(81%)	(80%)
Paxlovid	143	8,115	(98%)	(98%)	—	4,455	*	143	3,660	(96%)	(96%)
Eliquis[b]	1,762	1,745	1%	2%	1,152	1,064	8%	610	681	(10%)	(9%)
Prevnar family[d]	1,431	1,432	—	2%	868	909	(5%)	563	523	8%	12%
Nurtec ODT/Vydura	247	0	*	*	244	—	*	4	0	*	*
Premarin family	95	115	(18%)	(17%)	86	106	(19%)	9	9	(1%)	5%
FSME-IMMUN/TicoVac	101	68	49%	48%	2	1	*	100	67	48%	47%
All other Primary Care	616	690	(11%)	(7%)	213	208	3%	403	482	(16%)	(11%)
Specialty Care	**$ 3,656**	**$ 3,363**	**9%**	**12%**	**$ 1,619**	**$ 1,347**	**20%**	**$ 2,038**	**$ 2,015**	**1%**	**6%**
Vyndaqel family[e]	782	552	42%	43%	434	296	47%	348	256	36%	38%
Xeljanz	469	430	9%	11%	333	254	31%	136	176	(23%)	(19%)
Sulperazon	177	210	(15%)	(10%)	—	—	—	177	210	(15%)	(10%)
Enbrel (Outside the U.S. and Canada)	219	257	(15%)	(11%)	—	—	—	219	257	(15%)	(11%)
Inflectra	74	137	(46%)	(45%)	15	78	(81%)	59	59	—	3%
Zavicefta	132	100	32%	44%	—	—	—	132	100	32%	44%
Genotropin	74	91	(19%)	(13%)	(16)	15	*	90	76	18%	26%
BeneFIX	106	113	(7%)	(3%)	58	66	(13%)	48	47	2%	11%
Zithromax	44	54	(18%)	(13%)	0	0	(2%)	44	54	(18%)	(13%)
Oxbryta	77	—	*	—	76	—	*	1	—	*	—
Cibinqo	38	1	*	*	10	1	*	27	1	*	*
All other Hospital[f]	1,279	1,235	4%	6%	644	577	12%	635	659	(4%)	2%
All other Specialty Care	185	180	2%	7%	65	60	9%	120	121	(1%)	7%
Oncology	**$ 3,149**	**$ 3,263**	**(3%)**	**(2%)**	**$ 2,167**	**$ 2,179**	**(1%)**	**$ 983**	**$ 1,084**	**(9%)**	**(5%)**
Ibrance	1,247	1,320	(6%)	(4%)	850	868	(2%)	397	452	(12%)	(9%)
Oncology biosimilars[h]	363	434	(16%)	(16%)	259	323	(20%)	104	111	(7%)	(5%)
Xtandi[g]	423	400	6%	6%	423	400	6%	—	—	—	—
Inlyta	262	274	(4%)	(3%)	168	162	3%	94	112	(16%)	(12%)
Bosulif	154	156	(2%)	(1%)	106	102	4%	48	55	(12%)	(9%)
Lorbrena	121	77	58%	63%	53	41	29%	68	35	92%	*
Braftovi/Mektovi	113	121	(7%)	(7%)	110	121	(9%)	3	0	*	*
Xalkori	86	118	(27%)	(24%)	25	25	1%	61	93	(34%)	(31%)
Talzenna	12	13	(12%)	(10%)	6	7	(13%)	5	6	(12%)	(7%)
All other Oncology[i]	369	350	5%	9%	166	130	27%	203	220	(8%)	(2%)
BUSINESS INNOVATION	**$ 317**	**$ 319**	**(1%)**	**(0%)**	**$ 92**	**$ 89**	**3%**	**$ 225**	**$ 230**	**(2%)**	**(2%)**
Pfizer CentreOne[j]	307	319	(4%)	(4%)	82	89	(8%)	225	230	(2%)	(2%)
Pfizer Ignite	10	—	*	—	10	—	*	—	—	—	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 4,200**	**$ 9,171**	**(54%)**				
Pfizer Oncology Division					**$ 2,167**	**$ 2,179**	**(1%)**				
Pfizer International Division								**$ 6,323**	**$ 16,289**	**(61%)**	**(59%)**

Total Alliance revenues included above	**$ 1,967**	**$ 2,317**	**(15%)**	**(15%)**	**$ 1,522**	**$ 1,392**	**9%**	**$ 445**	**$ 924**	**(52%)**	**(51%)**
Total Royalty revenues included above	**$ 273**	**$ 217**	**26%**	**26%**	**$ 273**	**$ 217**	**26%**				

PFIZER INC. REVENUES
SIX MONTHS 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 31,492**	**$ 53,792**	**(41%)**	**(40%)**	**$ 15,169**	**$ 20,529**	**(26%)**	**$ 16,323**	**$ 33,262**	**(51%)**	**(48%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 30,863**	**$ 53,133**	**(42%)**	**(40%)**	**$ 14,965**	**$ 20,338**	**(26%)**	**$ 15,898**	**$ 32,795**	**(52%)**	**(48%)**
Primary Care	**$ 17,444**	**$ 39,912**	**(56%)**	**(55%)**	**$ 7,724**	**$ 13,565**	**(43%)**	**$ 9,721**	**$ 26,347**	**(63%)**	**(61%)**
Comirnaty[b][c]	4,552	22,076	(79%)	(78%)	345	3,396	(90%)	4,207	18,681	(77%)	(76%)
Paxlovid	4,212	9,585	(56%)	(54%)	1,960	5,470	(64%)	2,252	4,115	(45%)	(41%)
Eliquis[b]	3,636	3,537	3%	4%	2,413	2,144	13%	1,223	1,394	(12%)	(8%)
Prevnar family[d]	3,033	2,997	1%	3%	1,953	1,924	2%	1,081	1,074	1%	6%
Nurtec ODT/Vydura	414	1	*	*	406	—	*	7	1	*	*
Premarin family	207	217	(5%)	(4%)	190	200	(5%)	17	17	1%	7%
FSME-IMMUN/TicoVac	146	110	32%	34%	2	1	*	144	110	31%	33%
All other Primary Care	1,244	1,388	(10%)	(6%)	454	431	5%	790	956	(17%)	(11%)
Specialty Care	**$ 7,272**	**$ 6,873**	**6%**	**10%**	**$ 3,091**	**$ 2,628**	**18%**	**$ 4,181**	**$ 4,244**	**(2%)**	**5%**
Vyndaqel family[e]	1,468	1,164	26%	29%	818	561	46%	650	603	8%	12%
Xeljanz	706	802	(12%)	(10%)	423	457	(7%)	284	345	(18%)	(12%)
Sulperazon	497	420	18%	27%	—	—	—	497	420	18%	27%
Enbrel (Outside the U.S. and Canada)	419	537	(22%)	(17%)	—	—	—	419	537	(22%)	(17%)
Inflectra	252	272	(7%)	(5%)	134	157	(15%)	118	115	3%	7%
Zavicefta	248	204	22%	32%	—	—	—	248	204	22%	32%
Genotropin	222	171	30%	38%	52	22	*	170	148	14%	24%
BeneFIX	215	225	(5%)	(0%)	116	128	(9%)	99	98	1%	11%
Zithromax	194	180	8%	17%	1	1	(28%)	193	179	8%	17%
Oxbryta	148	—	*	—	146	—	*	1	—	*	—
Cibinqo	54	6	*	*	18	3	*	36	3	*	*
All other Hospital[f]	2,476	2,518	(2%)	1%	1,248	1,166	7%	1,229	1,352	(9%)	(3%)
All other Specialty Care	373	374	—	5%	135	133	1%	238	240	(1%)	8%
Oncology	**$ 6,146**	**$ 6,348**	**(3%)**	**(1%)**	**$ 4,150**	**$ 4,144**	**—**	**$ 1,997**	**$ 2,204**	**(9%)**	**(4%)**
Ibrance	2,391	2,557	(7%)	(5%)	1,600	1,621	(1%)	791	936	(16%)	(11%)
Oncology biosimilars[h]	775	894	(13%)	(12%)	559	676	(17%)	215	218	(1%)	4%
Xtandi[g]	763	743	3%	3%	763	743	3%	—	—	—	—
Inlyta	521	508	3%	5%	323	302	7%	199	206	(3%)	2%
Bosulif	304	284	7%	9%	211	184	15%	93	100	(8%)	(2%)
Lorbrena	234	149	57%	63%	105	80	30%	129	68	88%	*
Braftovi/Mektovi	215	225	(4%)	(4%)	209	224	(7%)	6	1	*	*
Xalkori	197	244	(19%)	(16%)	53	49	7%	144	195	(26%)	(21%)
Talzenna	22	24	(9%)	(5%)	11	13	(18%)	11	11	1%	10%
All other Oncology[i]	726	720	1%	5%	316	251	26%	410	469	(13%)	(6%)
BUSINESS INNOVATION	**$ 630**	**$ 659**	**(4%)**	**(3%)**	**$ 204**	**$ 192**	**7%**	**$ 425**	**$ 467**	**(9%)**	**(7%)**
Pfizer CentreOne[j]	615	659	(7%)	(5%)	190	192	(1%)	425	467	(9%)	(7%)
Pfizer Ignite	14	—	*	—	14	—	*	—	—	—	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 10,815**	**$ 16,194**	**(33%)**				
Pfizer Oncology Division					**$ 4,150**	**$ 4,144**	**—**				
Pfizer International Division								**$ 15,898**	**$ 32,795**	**(52%)**	**(48%)**

Total Alliance revenues included above	**$ 4,028**	**$ 4,631**	**(13%)**	**(12%)**	**$ 3,102**	**$ 2,779**	**12%**	**$ 926**	**$ 1,852**	**(50%)**	**(47%)**
Total Royalty revenues included above	**$ 477**	**$ 389**	**23%**	**23%**	**$ 477**	**$ 389**	**23%**				

PFIZER INC. REVENUES
THIRD-QUARTER 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 13,491**	**$ 22,876**	**(41%)**	**(41%)**	**$ 8,064**	**$ 14,090**	**(43%)**	**$ 5,427**	**$ 8,786**	**(38%)**	**(37%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 13,188**	**$ 22,556**	**(42%)**	**(41%)**	**$ 7,975**	**$ 13,986**	**(43%)**	**$ 5,214**	**$ 8,571**	**(39%)**	**(38%)**
Primary Care	**$ 6,310**	**$ 15,896**	**(60%)**	**(60%)**	**$ 4,112**	**$ 10,255**	**(60%)**	**$ 2,198**	**$ 5,641**	**(61%)**	**(60%)**
Comirnaty[b][c]	1,306	4,406	(70%)	(70%)	994	2,912	(66%)	312	1,494	(79%)	(79%)
Eliquis[b]	1,498	1,464	2%	3%	883	835	6%	615	628	(2%)	(1%)
Prevnar family[d]	1,843	1,610	14%	15%	1,299	1,093	19%	544	517	5%	5%
Paxlovid	202	7,514	(97%)	(97%)	—	5,044	*	202	2,470	(92%)	(91%)
Nurtec ODT/Vydura	233	0	*	*	227	—	*	6	0	*	*
Abrysvo	375	—	*	—	375	—	*	—	—	—	—
Premarin family	92	110	(17%)	(17%)	83	100	(18%)	9	10	(7%)	(4%)
FSME-IMMUN/TicoVac	91	67	37%	31%	1	1	16%	90	66	37%	31%
All other Primary Care	670	725	(8%)	(5%)	250	269	(7%)	420	456	(8%)	(4%)
Specialty Care	**$ 3,763**	**$ 3,407**	**10%**	**12%**	**$ 1,752**	**$ 1,490**	**18%**	**$ 2,011**	**$ 1,917**	**5%**	**7%**
Vyndaqel family[e]	892	602	48%	47%	511	329	55%	381	273	40%	36%
Xeljanz	503	502	—	1%	371	345	8%	132	157	(16%)	(15%)
Enbrel (Outside the U.S. and Canada)	208	230	(10%)	(7%)	—	—	—	208	230	(10%)	(7%)
Sulperazon	122	178	(32%)	(27%)	—	—	—	122	178	(32%)	(27%)
Genotropin	158	90	76%	79%	54	19	*	104	71	46%	51%
Zavicefta	130	98	33%	43%	—	—	—	130	98	33%	43%
Inflectra	121	131	(7%)	(8%)	61	70	(14%)	61	60	1%	(0%)
BeneFIX	107	99	7%	10%	54	53	3%	52	47	12%	19%
Zithromax	60	71	(16%)	(11%)	0	0	(17%)	59	70	(16%)	(11%)
Oxbryta	85	—	*	—	83	—	*	2	—	*	—
Cibinqo	37	11	*	*	8	3	*	28	8	*	*
All other Hospital[f]	1,139	1,210	(6%)	(5%)	538	594	(9%)	601	616	(2%)	0%
All other Specialty Care	202	185	9%	13%	71	77	(8%)	131	108	22%	28%
Oncology	**$ 3,115**	**$ 3,254**	**(4%)**	**(4%)**	**$ 2,111**	**$ 2,241**	**(6%)**	**$ 1,004**	**$ 1,013**	**(1%)**	**1%**
Ibrance	1,244	1,283	(3%)	(3%)	838	872	(4%)	406	411	(1%)	(1%)
Xtandi[g]	440	453	(3%)	(3%)	440	453	(3%)	—	—	—	—
Oncology biosimilars[h]	310	436	(29%)	(29%)	199	332	(40%)	111	104	6%	6%
Inlyta	252	252	—	1%	153	152	1%	98	100	(2%)	1%
Bosulif	160	141	14%	14%	114	93	22%	46	47	(3%)	(2%)
Lorbrena	159	99	61%	66%	60	49	23%	99	50	98%	*
Braftovi/Mektovi	131	126	4%	4%	126	124	1%	5	2	*	*
Xalkori	86	118	(27%)	(24%)	22	28	(22%)	64	89	(28%)	(24%)
Talzenna	20	13	60%	66%	13	7	84%	7	5	28%	41%
All other Oncology[i]	313	333	(6%)	(4%)	146	130	12%	168	203	(17%)	(13%)
BUSINESS INNOVATION	**$ 303**	**$ 320**	**(5%)**	**(7%)**	**$ 90**	**$ 104**	**(14%)**	**$ 214**	**$ 216**	**(1%)**	**(3%)**
Pfizer CentreOne[j]	293	319	(8%)	(10%)	79	103	(23%)	214	216	(1%)	(3%)
Pfizer Ignite	10	1	*	*	10	1	*	0	—	*	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 5,864**	**$ 11,745**	**(50%)**				
Pfizer Oncology Division					**$ 2,111**	**$ 2,241**	**(6%)**				
Pfizer International Division								**$ 5,214**	**$ 8,571**	**(39%)**	**(38%)**

Total Alliance revenues included above	**$ 1,645**	**$ 1,689**	**(3%)**	**(3%)**	**$ 1,236**	**$ 1,208**	**2%**	**$ 409**	**$ 482**	**(15%)**	**(18%)**
Total Royalty revenues included above	**$ 260**	**$ 239**	**9%**	**9%**	**$ 260**	**$ 239**	**9%**				

PFIZER INC. REVENUES
NINE MONTHS 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 44,984**	**$ 76,668**	**(41%)**	**(40%)**	**$ 23,233**	**$ 34,619**	**(33%)**	**$ 21,750**	**$ 42,049**	**(48%)**	**(46%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 44,051**	**$ 75,689**	**(42%)**	**(40%)**	**$ 22,939**	**$ 34,323**	**(33%)**	**$ 21,112**	**$ 41,366**	**(49%)**	**(46%)**
Primary Care	**$ 23,755**	**$ 55,808**	**(57%)**	**(56%)**	**$ 11,836**	**$ 23,820**	**(50%)**	**$ 11,919**	**$ 31,988**	**(63%)**	**(61%)**
Comirnaty[b][c]	5,858	26,483	(78%)	(77%)	1,339	6,308	(79%)	4,519	20,174	(78%)	(76%)
Eliquis[b]	5,135	5,001	3%	4%	3,296	2,979	11%	1,838	2,022	(9%)	(6%)
Prevnar family[d]	4,877	4,607	6%	7%	3,252	3,016	8%	1,624	1,591	2%	6%
Paxlovid	4,414	17,099	(74%)	(73%)	1,960	10,514	(81%)	2,454	6,584	(63%)	(60%)
Nurtec ODT/Vydura	646	1	*	*	633	—	*	13	1	*	*
Abrysvo	375	—	*	—	375	—	*	—	—	—	—
Premarin family	299	327	(9%)	(8%)	273	301	(9%)	26	27	(2%)	3%
FSME-IMMUN/TicoVac	237	177	34%	33%	2	1	78%	235	176	34%	33%
All other Primary Care	1,914	2,113	(9%)	(6%)	704	700	—	1,210	1,413	(14%)	(9%)
Specialty Care	**$ 11,035**	**$ 10,280**	**7%**	**11%**	**$ 4,843**	**$ 4,119**	**18%**	**$ 6,192**	**$ 6,161**	**1%**	**6%**
Vyndaqel family[e]	2,360	1,766	34%	35%	1,329	890	49%	1,031	876	18%	20%
Xeljanz	1,210	1,304	(7%)	(6%)	794	802	(1%)	416	502	(17%)	(13%)
Enbrel (Outside the U.S. and Canada)	627	767	(18%)	(14%)	—	—	—	627	767	(18%)	(14%)
Sulperazon	619	598	4%	11%	—	—	—	619	598	4%	11%
Genotropin	379	261	46%	52%	106	41	*	273	219	25%	32%
Zavicefta	378	302	25%	36%	—	—	—	378	302	25%	36%
Inflectra	373	403	(7%)	(6%)	195	228	(14%)	179	175	2%	5%
BeneFIX	321	325	(1%)	3%	171	180	(5%)	151	144	4%	13%
Zithromax	254	250	1%	9%	1	1	(25%)	253	249	2%	9%
Oxbryta	232	—	*	—	229	—	*	3	—	*	—
Cibinqo	91	17	*	*	27	6	*	64	11	*	*
All other Hospital[f]	3,616	3,728	(3%)	(1%)	1,786	1,760	1%	1,830	1,968	(7%)	(2%)
All other Specialty Care	575	558	3%	8%	206	210	(2%)	369	348	6%	14%
Oncology	**$ 9,261**	**$ 9,602**	**(4%)**	**(2%)**	**$ 6,260**	**$ 6,385**	**(2%)**	**$ 3,001**	**$ 3,217**	**(7%)**	**(2%)**
Ibrance	3,635	3,841	(5%)	(4%)	2,438	2,493	(2%)	1,197	1,347	(11%)	(8%)
Xtandi[g]	1,202	1,196	1%	1%	1,202	1,196	1%	—	—	—	—
Oncology biosimilars[h]	1,085	1,330	(18%)	(18%)	759	1,008	(25%)	326	322	1%	4%
Inlyta	773	760	2%	3%	476	454	5%	297	306	(3%)	1%
Bosulif	463	425	9%	11%	325	277	17%	139	148	(6%)	(2%)
Lorbrena	393	247	59%	64%	164	129	27%	228	118	93%	*
Braftovi/Mektovi	346	351	(1%)	(1%)	335	348	(4%)	11	3	*	*
Xalkori	283	362	(22%)	(18%)	75	78	(4%)	209	285	(27%)	(22%)
Talzenna	42	37	14%	19%	24	20	18%	18	17	10%	20%
All other Oncology[i]	1,039	1,053	(1%)	2%	462	382	21%	577	672	(14%)	(8%)
BUSINESS INNOVATION	**$ 933**	**$ 978**	**(5%)**	**(4%)**	**$ 294**	**$ 296**	**(1%)**	**$ 639**	**$ 683**	**(6%)**	**(6%)**
Pfizer CentreOne[j]	908	977	(7%)	(6%)	269	295	(9%)	639	683	(6%)	(6%)
Pfizer Ignite	25	1	*	*	25	1	*	0	—	*	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 16,679**	**$ 27,939**	**(40%)**				
Pfizer Oncology Division					**$ 6,260**	**$ 6,385**	**(2%)**				
Pfizer International Division								**$ 21,112**	**$ 41,366**	**(49%)**	**(46%)**

Total Alliance revenues included above	**$ 5,672**	**$ 6,320**	**(10%)**	**(10%)**	**$ 4,338**	**$ 3,987**	**9%**	**$ 1,335**	**$ 2,333**	**(43%)**	**(41%)**
Total Royalty revenues included above	**$ 737**	**$ 628**	**17%**	**17%**	**$ 737**	**$ 628**	**17%**				

PFIZER INC. REVENUES
FOURTH-QUARTER 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 14,570**	**$ 24,507**	**(41%)**	**(41%)**	**$ 4,912**	**$ 8,698**	**(44%)**	**$ 9,657**	**$ 15,809**	**(39%)**	**(39%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 14,186**	**$ 24,136**	**(41%)**	**(42%)**	**$ 4,810**	**$ 8,597**	**(44%)**	**$ 9,376**	**$ 15,539**	**(40%)**	**(40%)**
Primary Care	**$ 7,044**	**$ 17,373**	**(59%)**	**(60%)**	**$ 845**	**$ 4,840**	**(83%)**	**$ 6,200**	**$ 12,533**	**(51%)**	**(51%)**
Comirnaty[b][c]	5,361	11,326	(53%)	(54%)	1,064	2,469	(57%)	4,297	8,857	(51%)	(53%)
Eliquis[b]	1,612	1,479	9%	9%	931	843	10%	681	636	7%	7%
Prevnar family[d]	1,624	1,734	(6%)	(6%)	1,012	1,020	(1%)	612	714	(14%)	(14%)
Paxlovid[k]	(3,135)	1,834	*	*	(3,249)	(0)	*	114	1,834	(94%)	(95%)
Nurtec ODT/Vydura	282	211	33%	33%	275	211	31%	7	1	*	*
Abrysvo	515	—	*	—	513	—	*	2	—	*	—
Premarin family	98	128	(23%)	(23%)	88	119	(26%)	10	9	13%	13%
FSME-IMMUN/TicoVac	30	23	33%	24%	0	1	(57%)	30	22	36%	27%
All other Primary Care	657	637	3%	5%	210	178	18%	447	460	(3%)	1%
Specialty Care	**$ 3,953**	**$ 3,571**	**11%**	**11%**	**$ 1,776**	**$ 1,558**	**14%**	**$ 2,178**	**$ 2,013**	**8%**	**9%**
Vyndaqel family[e]	961	680	41%	39%	534	355	51%	427	326	31%	27%
Xeljanz	493	493	—	0%	360	327	10%	133	165	(19%)	(19%)
Enbrel (Outside the U.S. and Canada)	203	236	(14%)	(12%)	—	—	—	203	236	(14%)	(12%)
Sulperazon	138	189	(27%)	(25%)	—	—	—	138	189	(27%)	(25%)
Genotropin	160	99	61%	65%	47	27	75%	112	72	55%	61%
Zavicefta	133	109	22%	31%	(0)	—	*	133	109	22%	31%
Inflectra	117	129	(10%)	(11%)	63	62	1%	54	68	(19%)	(22%)
BeneFIX	103	101	2%	5%	54	54	(1%)	49	46	6%	11%
Zithromax	152	81	89%	91%	0	1	(70%)	152	80	90%	93%
Oxbryta	96	73	32%	32%	94	72	30%	2	0	*	*
Cibinqo	37	10	*	*	20	6	*	18	5	*	*
All other Hospital[f]	1,143	1,187	(4%)	(3%)	524	584	(10%)	620	603	3%	3%
All other Specialty Care	217	185	17%	21%	80	71	14%	136	114	19%	26%
Oncology	**$ 3,189**	**$ 3,192**	**—**	**0%**	**$ 2,190**	**$ 2,198**	**—**	**$ 999**	**$ 993**	**1%**	**1%**
Ibrance	1,118	1,279	(13%)	(13%)	712	876	(19%)	405	403	1%	(1%)
Xtandi[g]	457	454	1%	1%	457	454	1%	—	—	—	—
Oncology biosimilars[h]	322	423	(24%)	(24%)	207	302	(31%)	115	121	(5%)	(4%)
Inlyta	263	243	8%	9%	166	164	1%	97	79	24%	27%
Bosulif	182	150	21%	21%	120	98	22%	62	52	19%	19%
Lorbrena	146	95	53%	55%	60	48	25%	86	47	82%	86%
Braftovi/Mektovi	131	105	25%	27%	129	104	24%	2	1	*	*
Xalkori	91	103	(12%)	(10%)	25	27	(7%)	66	76	(13%)	(11%)
Talzenna	22	11	95%	*	16	4	*	6	7	(14%)	(2%)
Adcetris[l]	56	—	*	—	56	—	*	—	—	—	—
Padcev[l]	53	—	*	—	53	—	*	—	—	—	—
Tukysa[l]	18	—	*	—	18	—	*	—	—	—	—
Tivdak[l]	4	—	*	—	4	—	*	—	—	—	—
All other Oncology[i]	325	328	(1%)	0%	165	120	38%	160	208	(23%)	(22%)
BUSINESS INNOVATION	**$ 383**	**$ 371**	**3%**	**2%**	**$ 102**	**$ 101**	**1%**	**$ 281**	**$ 269**	**4%**	**2%**
Pfizer CentreOne[j]	364	365	—	(2%)	83	96	(14%)	281	269	4%	2%
Pfizer Ignite	20	5	*	*	20	5	*	(0)	—	*	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 2,620**	**$ 6,398**	**(59%)**				
Pfizer Oncology Division					**$ 2,190**	**$ 2,198**	**—**				
Pfizer International Division								**$ 9,376**	**$ 15,539**	**(40%)**	**(40%)**

Total Alliance revenues included above	**$ 1,910**	**$ 2,217**	**(14%)**	**(15%)**	**$ 1,290**	**$ 1,216**	**6%**	**$ 620**	**$ 1,001**	**(38%)**	**(40%)**
Total Royalty revenues included above	**$ 321**	**$ 217**	**48%**	**48%**	**$ 321**	**$ 217**	**48%**				

PFIZER INC. REVENUES
TWELVE MONTHS 2023 and 2022
UNAUDITED
(millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL			
			% of Change				% of Change			% of Change	
	2023	2022	Reported	Operational	2023	2022	Reported	2023	2022	Reported	Operational
TOTAL REVENUES[a]	**$ 59,553**	**$ 101,175**	**(41%)**	**(40%)**	**$ 28,145**	**$ 43,317**	**(35%)**	**$ 31,408**	**$ 57,858**	**(46%)**	**(44%)**
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)	**$ 58,237**	**$ 99,826**	**(42%)**	**(41%)**	**$ 27,749**	**$ 42,920**	**(35%)**	**$ 30,488**	**$ 56,905**	**(46%)**	**(45%)**
Primary Care	**$ 30,799**	**$ 73,181**	**(58%)**	**(57%)**	**$ 12,680**	**$ 28,661**	**(56%)**	**$ 18,119**	**$ 44,521**	**(59%)**	**(58%)**
Comirnaty[b][c]	11,220	37,809	(70%)	(70%)	2,404	8,778	(73%)	8,816	29,032	(70%)	(69%)
Eliquis[b]	6,747	6,480	4%	5%	4,228	3,822	11%	2,519	2,658	(5%)	(3%)
Prevnar family[d]	6,501	6,342	3%	4%	4,265	4,037	6%	2,236	2,305	(3%)	(0%)
Paxlovid[k]	1,279	18,933	(93%)	(92%)	(1,289)	10,514	*	2,568	8,419	(69%)	(68%)
Nurtec ODT/Vydura	928	213	*	*	908	211	*	20	2	*	*
Abrysvo	890	—	*	—	888	—	*	2	—	*	—
Premarin family	397	455	(13%)	(13%)	361	420	(14%)	36	36	2%	6%
FSME-IMMUN/TicoVac	268	200	34%	32%	3	2	26%	265	198	34%	32%
All other Primary Care	2,571	2,750	(7%)	(3%)	914	878	4%	1,657	1,872	(12%)	(7%)
Specialty Care	**$ 14,988**	**$ 13,851**	**8%**	**11%**	**$ 6,619**	**$ 5,676**	**17%**	**$ 8,370**	**$ 8,174**	**2%**	**7%**
Vyndaqel family[e]	3,321	2,447	36%	36%	1,863	1,245	50%	1,458	1,202	21%	22%
Xeljanz	1,703	1,796	(5%)	(4%)	1,154	1,129	2%	549	668	(18%)	(15%)
Enbrel (Outside the U.S. and Canada)	830	1,003	(17%)	(14%)	—	—	—	830	1,003	(17%)	(14%)
Sulperazon	757	786	(4%)	2%	—	—	—	757	786	(4%)	2%
Genotropin	539	360	50%	56%	153	68	*	386	292	32%	39%
Zavicefta	511	412	24%	34%	(0)	—	*	511	412	24%	34%
Inflectra	490	532	(8%)	(7%)	257	289	(11%)	233	243	(4%)	(3%)
BeneFIX	424	425	—	3%	225	235	(4%)	200	191	5%	13%
Zithromax	406	331	23%	29%	1	2	(41%)	404	328	23%	29%
Oxbryta	328	73	*	*	323	72	*	5	0	*	*
Cibinqo	128	27	*	*	46	11	*	81	16	*	*
All other Hospital[f]	4,759	4,915	(3%)	(1%)	2,310	2,344	(1%)	2,450	2,572	(5%)	(1%)
All other Specialty Care	792	743	7%	11%	286	281	2%	506	462	9%	17%
Oncology	**$ 12,450**	**$ 12,794**	**(3%)**	**(2%)**	**$ 8,450**	**$ 8,583**	**(2%)**	**$ 4,000**	**$ 4,210**	**(5%)**	**(1%)**
Ibrance	4,753	5,120	(7%)	(6%)	3,151	3,370	(6%)	1,602	1,751	(8%)	(6%)
Xtandi[g]	1,659	1,650	1%	1%	1,659	1,650	1%	—	—	—	—
Oncology biosimilars[h]	1,407	1,753	(20%)	(19%)	966	1,310	(26%)	441	443	(1%)	2%
Inlyta	1,036	1,003	3%	5%	642	618	4%	394	385	3%	7%
Bosulif	645	575	12%	13%	444	375	19%	200	200	—	3%
Lorbrena	539	343	57%	62%	224	177	27%	314	166	90%	99%
Braftovi/Mektovi	477	456	5%	5%	465	452	3%	13	4	*	*
Xalkori	374	465	(20%)	(16%)	100	105	(4%)	274	361	(24%)	(20%)
Talzenna	64	48	33%	38%	40	25	61%	24	23	3%	14%
Adcetris[i]	56	—	*	—	56	—	*	—	—	—	—
Padcev[i]	53	—	*	—	53	—	*	—	—	—	—
Tukysa[i]	18	—	*	—	18	—	*	—	—	—	—
Tivdak[i]	4	—	*	—	4	—	*	—	—	—	—
All other Oncology[i]	1,364	1,381	(1%)	2%	627	502	25%	737	879	(16%)	(11%)
BUSINESS INNOVATION	**$ 1,316**	**$ 1,349**	**(2%)**	**(3%)**	**$ 396**	**$ 397**	**—**	**$ 920**	**$ 952**	**(3%)**	**(3%)**
Pfizer CentreOne[j]	1,272	1,342	(5%)	(5%)	352	390	(10%)	920	952	(3%)	(3%)
Pfizer Ignite	44	7	*	*	44	7	*	—	—	—	—

Biopharma

Pfizer U.S. Commercial Division (U.S. Primary Care and U.S. Specialty Care)					**$ 19,299**	**$ 34,337**	**(44%)**				
Pfizer Oncology Division					**$ 8,450**	**$ 8,583**	**(2%)**				
Pfizer International Division								**$ 30,488**	**$ 56,905**	**(46%)**	**(45%)**

Total Alliance revenues included above	**$ 7,582**	**$ 8,537**	**(11%)**	**(11%)**	**$ 5,628**	**$ 5,203**	**8%**	**$ 1,955**	**$ 3,335**	**(41%)**	**(41%)**
Total Royalty revenues included above	**$ 1,058**	**$ 845**	**25%**	**25%**	**$ 1,058**	**$ 845**	**25%**				

PFIZER INC.
NOTES TO REVENUES TABLE INFORMATION
(UNAUDITED)

(a) In the first quarter of 2024, we reclassified royalty income (substantially all of which related to Biopharma) from *Other (income)/deductions—net* and began presenting *Royalty revenues* as a separate line within *Total revenues* in our consolidated statements of income. Prior-period amounts have been recast to conform to the current period presentation.

(b) Primarily reflects product revenues and alliance revenues.

(c) Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See footnote (j) below.

(d) Prevnar family includes revenues from Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult).

(e) Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.

(f) Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig portfolio.

(g) Primarily reflects alliance revenues and royalty revenues.

(h) Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera, Nivestym and Nyvepria.

(i) Includes revenues for Bavencio which, prior to June 30, 2023, were recorded as Alliance revenues under our agreement with Merck KGaA to co-develop and co-commercialize Bavencio (avelumab). Effective June 30, 2023, our alliance terminated and Merck KGaA took full control of the global commercialization of Bavencio. Beginning in the third quarter of 2023, the related profit share was replaced by a 15% royalty to Pfizer on net sales of Bavencio. Effective January 1, 2024, we no longer record royalties from U.S. sales of Bavencio, as we have irrevocably chosen to donate the right to such royalties to the American Association for Cancer Research**.** We and Merck KGaA continue to operationalize our respective ongoing clinical trials for Bavencio; and Merck KGaA controls all future R&D activities. Bavencio is a registered trademark of Merck KGaA.

(j) PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships.

(k) Includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.

(l) Represents revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023.

* Indicates calculation not meaningful.

Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts.